杨晓明,侯继峰
YANG Xiao-ming,HOU Ji-feng

• 1:中国生物技术股份有限公司
• 2:中国食品药品检定研究院血液室

摘要(Abstract)：

随着康复期血浆(convalescent plasma,CP)被成功地用于治疗多种急性病毒性传染病,其独到的治疗技术优势越来越受到肯定和认同。新近在中国武汉发现并鉴定一种命名为2019-nCoV(SARS-CoV-2)的新型冠状病毒,目前暂无特异性治疗其感染的有效手段。本文就CP应用于埃博拉、大流行流感、严重急性呼吸综合征(severe acute respiratory syndrome,SARS)、中东呼吸综合征(Middle East respiratory syndrome,MERS)的现状作一综述,并对其治疗新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)的前景作一展望。
With the successful application of convalescent plasma(CP) in various acute viral infectious diseases,the unique advantage of the therapy has been paid more and more attentions. Recently,a novel coronavirus named as 2019-nCoV(SARS-CoV-2)was discovered and identified in Wuhan,China. Up to now,there has been no specific treatment for 2019-nCoV(SARS-CoV-2) infection. This paper describes the current status of application of CP in Ebola,pandemic influenza,severe acute respiratory syndrome(SARS) and Middle East respiratory syndrome(MERS) as well as the prospect of CP in therapy of COVID-19.

关键词(KeyWords)： 康复期血浆;大流行流感病毒;埃博拉病毒;SARS冠状病毒;MERS冠状病毒;新型冠状病毒;新型冠状病毒肺炎
Convalescent plasma(CP);Pandemic influenza virus;Ebola virus;SARS-CoV;MERS-CoV;2019-nCoV(SARS-CoV-2);COVID-19

Abstract:

Keywords:

基金项目(Foundation): 国家科技部重点专项“2019-nCoV感染恢复期患者特异性血浆和特异性球蛋白的制备”(2020YFC-0841800)

作者(Author): 杨晓明,侯继峰
YANG Xiao-ming,HOU Ji-feng

DOI: 10.13200/j.cnki.cjb.003023

参考文献(References)：

• [1]EXNER SIMON L P A.Experimentalpoliomyelitisinmonkeys.SeventhNote:activeimmunization and passive serum protection[J].JAMA,1910,LIV:1780-1782.
• [2]LEIDER J P,BRUNKER P A,NESS P M.Convalescent transfusion for pandemic influenza:preparing blood banks for a new plasma product[J].Transfusion,2010,50(6):1384-1398.
• [3]CHENG Y,WONG R,SOO Y O,et al.Use of convalescent plasma therapy in SARS patients in Hong Kong[J].Eur J Clin Microbiol Infect Dis,2005,24(1):44-46.
• [4]ARABI Y,BALKHY H,HAJEER A H,et al.Feasibility,safety,clinical,and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection:a study protocol[J].Springerplus,2015,4(1):709.
• [5]HUNG F,TO K K,LEE C K,et al.Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A(H1N1)2009 virus infection[J].Clin Infect Dis,2011,52(4):447-456.
• [6]FRAME J D,VERBRUGGE G P,GILL R G,et al.The use of Lassa fever convalescent plasma in Nigeria[J].Trans R Soc Trop Med Hyg,1984,78(3):319-324.
• [7]MAIR-JENKINS J,SAAVEDRA-CAMPOS M,BAILLIE J K,et al.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology:a systematic review and exploratory meta-analysis[J].J Infect Dis,2015,211(1):80-90.
• [8]Report of an International Commission.Ebola haemorrhagic fever in Zaire,1976[J].Bull World Health Organ,1978,56(2):271-293.
• [9]EMOND R T,EVANS B,BOWEN E T,et al.A case of Ebola virus infection[J].Br Med J,1977,2(6086):541-544.
• [10]MUPAPA K,MASSAMBA M,KIBADI K,et al.Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients.International Scientific and Technical Committee[J].J Infect Dis,1999,179(Suppl 1):S18-S23.
• [11]VAN GRIENSVEN J,De WEIGGGELEIRE A,DELAMOU A,et al.The use of Ebola convalescent plasma to treat Ebola virus disease in resource-constrained settings:a perspective from the field[J].Clin Infect Dis,2016,62(1):69-74.
• [12]MORA-RILLO M,ARSUAGA M,RAMIREZ-OLIVENCIA G,et al.Acute respiratory distress syndrome after convalescent plasma use:treatment of a patient with Ebola virus disease contracted in Madrid,Spain[J].Lancet Respir Med,2015,3(7):554-562.
• [13]VAN GRIENSVEN J,EDWARDS T,DE LAMBALLERIE X,et al.Evaluation of convalescent plasma for Ebola virus disease in guinea[J].N Engl J Med,2016,374(1):33-42.
• [14]HUNG I F,TO K K,LEE C K,et al.Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A(H1N1)2009 virus infection[J].Clin Infect Dis,2011,52(4):447-456.
• [15]HANSON B J,BOON A C,LIM A P,et al.Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice[J].Respir Res,2006,7:126.
• [16]ZHOU B,ZHONG N,GUAN Y.Treatment with convalescent plasma for influenza A(H5N1)infection[J].N Engl J Med,2007,357(14):1450-1451.
• [17]KSIAZEK T G,ERDMAN D,GOLDSMITH C S,et al.Anovel coronavirus associated with severe acute respiratory syndrome[J].N Engl J Med,2003,348(20):1953-1966.
• [18]DROSTEN C,GUNTHER S,PREISER W,et al.Identification of a novel coronavirus in patients with severe acute respiratory syndrome[J].N Engl J Med,2003,348(20):1967-1976.
• [19]PEIRIS J S,LAI S T,POON L L,et al.Coronavirus as a possible cause of severe acute respiratory syndrome[J].Lancet,2003,361(9366):1319-1325.
• [20]RABENAU H F,BIESERT L,SCHMIDT T,et al.SARS-coronavirus(SARS-CoV)and the safety of a solvent/detergent(S/D)treated immunoglobulin preparation[J].Biologicals,2005,33(2):95-99.
• [21]ZAKI AM,VAN BOHEEMEN S,BESTEBROER TM,et al.Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia[J].N Engl J Med,2012,367(19):1814-1820.
• [22]World Health Organization.Middle East respiratory syndrome coronavirus(MERS-CoV)[EB/OL].(2019-11-30)[2020-02-18].http：//www.who.int/emergencies/mers-cov/en/.
• [23]MAIR-JENKINS J,SAAVEDRA-CAMPOS M,Baillie J K,et al.The effectiveness of convalescent plasma and hyperimmune imm-unoglobulin for the treatment of severe acute respiratory infections of viral etiology:a systematic review and exploratory meta-analysis[J].J Infect Dis,2015,211(1):80-90.
• [24]KO J H,SEOK H,CHO S Y,et al.Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection:a single centre experience[J].Antivir Ther,2018,23(7):617-622.
• [25]World Health Organization.Novel coronavirus(2019-n CoV)situation report-15[EB/OL].(2020-02-04)[2020-02-05].https：//www.who.int/docs/default-source/coronaviruse/situationreports/20200204-sitrep-15-ncov.pdf?sfvrsn=88fe8ad6_2.
• [26]WANG D,HU B,HU C,et al.Clinical characteristics of 138hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan,China[J].JAMA,Published online February07,2020.
• [27]LOZANO M,CID J,MULLER T H.Plasma treated with methylene blue and light:clinical efficacy and safety profile[J].Transfus Med Rev,2013,27(4):235-240.
• [28]MARKUS EICKMANN,UTE GRAVEMANN,WIEBKE HAD-KE,et al.Inactivation of Ebola virus and Middle East respirato-ry syndrome coronavirus in platelet concentrates and plasma by ultraviolet light and methylene blue plus visible light,respectively[J].Transfusion,2018,58(9):2202-2207.
• [29]NOENS L,VILARINO M D,MEGALOU A,et al.International,prospective haemovigilance study on methylene blue-treated plasma[J].Vox Sang,2017,112(4):352-359.
• [30]KRAFT C S,HEWLETT A L,KOEPSELL S,et al.The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States[J].Clin Infect Dis,2015,61(4):496-502.
• [31]CAO WC,LIU W,ZHANG PH,et al.Disappearance of antibodies to SARS-associated coronavirus after recovery[J].N Engl J Med,2007,357(9797):1162-1163.
• [32]XIE L,LIU Y,FAN B,et al.Dynamic changes of serum SARS-coronavirus IgG,pulmonary function and radiography in patients recovering from SARS after hospital discharge[J].Respir Res,2005,6(1):5.